Eli Lilly terminates migraine prophylaxi
(NewsTraders) -- Synaptic Pharmaceutical Corp.
(SNAP) disclosed in a Form 8-K filing that Eli Lilly
decided to terminate a drug discovery program with
Synaptic focused on the identification and development of
serotonin 2B antagonists for the prophylactic treatment of
migraine.
Lilly had previously determined, based upon competing
priorities, to discontinue development of the compound, which
was undergoing late preclinical testing, and to seek
a licensee or development partner for the
compound.
As a result of the most-recent decision, Lilly will
no longer seek a licensee or development partner for
the compound.
Synaptic had announced on
September 3 that the migraine compound which the program
centered on would advance into Phase III clinical trials.